Budd-chiari syndrome and essential thrombocythemia in a child: Favorable outcome after transjugular intrahepatic portosystemic shunt

Journal of Pediatric Gastroenterology and Nutrition

Volumn 46, Issue 3, 2008, Pages 334-337

  Hermeziu, Bogdan ^a   Franchi Abella, Stéphanie ^b   Plessier, Aurélie ^c   Habes, Dalila ^a   Mosca, Alexis ^d   Sibert, Annie ^e   Bernard, Olivier ^a   Pariente, Danièle ^b   Jacquemin, Emmanuel ^a  

^a Pediatric Hepatology and National Reference Centre for Biliary Atresia   (France)

^b BICÊTRE HOSPITAL   (France)

^c Departments of Hepatology   (France)

^d ARMAND TROUSSEAU HOSPITAL   (France)

^e BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BUDD CHIARI SYNDROME; CASE REPORT; CHILD; FEMALE; HUMAN; LIVER VEIN; METHODOLOGY; THROMBOCYTOPENIA; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; TREATMENT OUTCOME;

BUDD-CHIARI SYNDROME; CHILD; FEMALE; HEPATIC VEINS; HUMANS; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 43049183369     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0b013e31814d4e0a     Document Type: Article

References (26)

1. Zimmerman MA, Cameron AM, Ghobrial RM. Budd-Chiari syndrome. Clin Liver Dis 2006; 10:259-273.
2. Murad SD, Valla DC, de Groen PC, et al. Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology 2004; 39:500-508.
3. Plessier A, Sibert A, Consigny Y, et al. Aiming at minimal invasiveness as a therapeutic strategy for Budd-Chiari syndrome. Hepatology 2006; 44:1308-1316.
4. Brancaccio V, Iannaccone L, Margaglione M, et al. Multiple thrombophilic factors in a patient with Budd-Chiari syndrome. Clin Lab Haematol 2002; 24:61-63.
5. Brunerova L, Bartakova H, Jankovska M, et al. The Budd-Chiari syndrome in a patient with primary thrombocythemia treated with interferon alfa and transjugular portosystemic shunt. Cas Lek Cesk 2004; 143:198-201.
6. Corredoira JC, Gonzalez M, Casariego E, et al. Budd-Chiari syndrome as a preceding phase of essential thrombocythemia. Sangre (Barc) 1989; 34:381.
7. Anger BR, Seifried E, Scheppach J, et al. Budd-Chiari syndrome and thrombosis of other abdominal vessels in the chronic myeloproliferative diseases. Klin Wochenschr 1989; 67:818-825.
8. Garza Trasobares E, Gonzalez Sanz-Agero P, et al. Budd-Chiari syndrome in a case of essential thrombocythemia. Rev Esp Enferm Apar Dig 1988; 73:64-66.
9. Gentil-Kocher S, Bernard O, Brunelle F, et al. Budd-Chiari syndrome in children: report of 22 cases. J Pediatr 1988; 113:30-38.
10. Cario H, Pahl HL, Schwarz K, et al. Familial polycythemia vera with Budd-Chiari syndrome in childhood. Br J Haematol 2003; 123:346-352.
11. Cobo F, Cervantes F, Garcia-Pagan JC, et al. Budd-Chiari syndrome associated with chronic myeloproliferative syndromes: analysis of 6 cases. Med Clin (Barc) 1996; 107:660-663.
12. Eapen CE, Velissaris D, Heydtmann M, et al. Favourable medium term outcome following hepatic vein recanalisation and/or transjugular intrahepatic portosystemic shunt for Budd Chiari syndrome. Gut 2006; 55:878-884.
13. Melear JM, Goldstein RM, Levy MF, et al. Hematologic aspects of liver transplantation for Budd-Chiari syndrome with special reference to myeloproliferative disorders. Transplantation 2002; 74:1090-1095.
14. Lang H, Oldhafer KJ, Kupsch E, et al. Liver transplantation for Budd-Chiari syndrome: palliation or cure? Transpl Int 1994; 7:115-119.
15. Opitz T, Buchwald AB, Lorf T, et al. The transjugular intrahepatic portosystemic stent-shunt (TIPS) as rescue therapy for complete Budd-Chiari syndrome and portal vein thrombosis. Z Gastroenterol 2003; 41:413-418.
16. Safka V, Hulek P, Krajina A, et al. Budd-Chiari syndrome and TIPS: twelve years’ experience. Cas Lek Cesk 2005; 144(Suppl 3):38-42.
17. Khuroo MS, Al-Suhabani H, Al-Sebayel M, et al. Budd-Chiari syndrome: long-term effect on outcome with transjugular intrahepatic portosystemic shunt. J Gastroenterol Hepatol 2005; 20:1494-1502.
18. Min AD, Atillasoy EO, Schwartz ME, et al. Reassessing the role of medical therapy in the management of hepatic vein thrombosis. Liver Transpl Surg 1997; 3:423-429.
19. Pagliuca A, Mufti GJ, Janossa-Tahernia M, et al. in vitro colony culture and chromosomal studies in hepatic and portal vein thrombosis: possible evidence of an occult myeloproliferative state. Q J Med 1990; 76:981-989.
20. Valla D, Casadevall N, Lacombe C, et al. Primary myeloproliferative disorder and hepatic vein thrombosis: a prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome. Ann Intern Med 1985; 103:329-334.
21. Primignani M, Barosi G, Bergamaschi G, et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology 2006; 44:1528-1534.
22. Cheung B, Radia D, Pantelidis P, et al. The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia. Br J Haematol 2006; 132:244-245.
23. Patel RK, Lea NC, Heneghan MA, et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology 2006; 130:2031-2038.
24. Bellanne-Chantelot C, Chaumarel I, Labopin M, et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood 2006; 108:346-352.
25. Dubuisson C, Boyer-Neumann C, Wolf M, et al. Protein C, protein S and antithrombin III in children with portal vein obstruction. J Hepatol 1997; 27:132-135.
26. Lazareth I, Delarue R, Priollet P. When should a myeloproliferative syndrome be suggested in vascular medicine? J Mal Vasc 2005; 30:46-52.